Vitiligo affects approximately 1-2% of the Indian population — a disproportionately visible number given the contrast between depigmented patches and the typically darker Indian skin tone. The psychological and social impact is significant, and yet many patients arrive having never received a clear explanation of what vitiligo is, what drives it, or what treatment can realistically offer. This is that explanation.

What Vitiligo Is

Vitiligo is an autoimmune condition in which CD8+ cytotoxic T cells target and destroy melanocytes — the pigment-producing cells of the skin. The result is areas of complete pigment loss that appear as white or ivory patches. It can affect any area of the body and follows no predictable pattern — it may remain localised and stable for years or progress to involve large body surface areas. Segmental vitiligo (affecting one segment of the body, often following a nerve distribution) tends to stabilise relatively quickly; non-segmental vitiligo is typically more progressive.

Triggers and Associations

Vitiligo has a strong genetic component but requires environmental or immunological triggers to initiate or worsen. Common triggers include: physical trauma to the skin (the Koebner phenomenon), emotional stress, sunburn, and certain chemical exposures. It is associated with other autoimmune conditions — thyroid disease (particularly Hashimoto’s thyroiditis), type 1 diabetes, and alopecia areata — and screening for these associations is part of the standard work-up at our clinic.

Modern Treatment Options

Treatment aims to stop progression and restore pigment to depigmented areas. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are first-line for localised vitiligo, particularly on the face — they modulate the local immune response without the skin atrophy risk of topical steroids. Narrowband UVB phototherapy is the most effective treatment for active, widespread vitiligo, stimulating melanocyte migration from the edges of lesions and from hair follicle reservoirs. JAK inhibitors — particularly ruxolitinib cream — have shown remarkable results in clinical trials and represent a significant advance in topical vitiligo treatment. For stable vitiligo that has not responded to medical management, surgical options including melanocyte transplantation are available at specialist centres. The key message: vitiligo in 2026 is significantly more treatable than it was a decade ago. Early treatment during the active phase produces the best outcomes.

Book a consultation: wa.me/919381218003
— Dr. Nishita Ranka | Consultant Dermatologist | Dr. Nishita’s Clinic for Skin, Hair & Aesthetics, Hyderabad